Publications
Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge
Jang H, Meyers LM, Boyle C, De Groot AS, Moise L, Ross TM
PMID:
Abstract
The influenza hemagglutinin (HA) isolated from avian H7N9 influenza virus strains elicit weak immune responses. This low immunogenicity may be due to a regulatory T cell (T)-stimulating epitopes in HA from the H7N9 isolate A/Anhui/1/2013 (Anh/13). In this report, this T stimulating sequence was removed from the wild-type (WT) H7 HA amino acid sequence and replaced with a conserved CD4聽+聽T cell stimulating sequences from human seasonal H3N2 strains and designed OPT1 H7 HA. The effectiveness of this optimized H7 HA protein was determined using a humanized mouse (HLA-DR3) expressing the human leukocyte antigen (HLA) DR3 allele. HLA-DR3 mice were pre-immunized by infecting with H3N2 influenza virus, A/Hong Kong/4108/2014 and then vaccinated intramuscularly with either the WT H7聽HA from Anh/13 or the OPT1 H7聽HA antigen without adjuvant. The OPT1 H7聽HA vaccination group elicited higher H7聽HA-specific IgG titers that resulted in a lower mortality, weight loss, and lung viral titer following lethal challenge with the H7N9 Anh/13 influenza virus compared to WT-vaccinated mice. Overall, T-cell epitope-engineered vaccines can improve the immunogenicity of H7聽HA antigens resulting in enhanced survival and lower morbidity against H7N9 influenza virus challenge.
This publication is listed for reference purposes only. It may be included to present a more complete view of a 小蓝俱乐部employee's body of work, or as a reference to a 小蓝俱乐部sponsored project.